Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of RK-023 in male patients with androgenetic alopecia
jRCT2080220997Phase 2
- Sponsor
- R-Tech Ueno
- Start
- Feb 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in androgenetic alopecia (AGA) comparing RK-023 with Placebo (2 arms). Primary endpoints: Safety of RK-023 and Preliminary hair regrowth.
02
Drugs
unoprostone isopropyl
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on jRCT2080220997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220997.